396 related articles for article (PubMed ID: 27716615)
1. PITX2 and PANCR DNA methylation predicts overall survival in patients with head and neck squamous cell carcinoma.
Sailer V; Holmes EE; Gevensleben H; Goltz D; Dröge F; de Vos L; Franzen A; Schröck F; Bootz F; Kristiansen G; Schröck A; Dietrich D
Oncotarget; 2016 Nov; 7(46):75827-75838. PubMed ID: 27716615
[TBL] [Abstract][Full Text] [Related]
2. DNA Methylation of PITX2 and PANCR Is Prognostic for Overall Survival in Patients with Resected Adenocarcinomas of the Biliary Tract.
Uhl B; Dietrich D; Branchi V; Semaan A; Schaefer P; Gevensleben H; Rostamzadeh B; Lingohr P; Schäfer N; Kalff JC; Kristiansen G; Matthaei H
PLoS One; 2016; 11(10):e0165769. PubMed ID: 27798672
[TBL] [Abstract][Full Text] [Related]
3. Clinical performance validation of PITX2 DNA methylation as prognostic biomarker in patients with head and neck squamous cell carcinoma.
Sailer V; Gevensleben H; Dietrich J; Goltz D; Kristiansen G; Bootz F; Dietrich D
PLoS One; 2017; 12(6):e0179412. PubMed ID: 28617833
[TBL] [Abstract][Full Text] [Related]
4.
Sailer V; Holmes EE; Gevensleben H; Goltz D; Dröge F; Franzen A; Dietrich J; Kristiansen G; Bootz F; Schröck A; Dietrich D
Clin Epigenetics; 2017; 9():12. PubMed ID: 28174607
[TBL] [Abstract][Full Text] [Related]
5. Intragenic DNA methylation of PITX1 and the adjacent long non-coding RNA C5orf66-AS1 are prognostic biomarkers in patients with head and neck squamous cell carcinomas.
Sailer V; Charpentier A; Dietrich J; Vogt TJ; Franzen A; Bootz F; Dietrich D; Schroeck A
PLoS One; 2018; 13(2):e0192742. PubMed ID: 29425237
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients.
Dietrich D; Hasinger O; Liebenberg V; Field JK; Kristiansen G; Soltermann A
Diagn Mol Pathol; 2012 Jun; 21(2):93-104. PubMed ID: 22555092
[TBL] [Abstract][Full Text] [Related]
7. Circulating Cell-Free SEPT9 DNA Methylation in Blood Is a Biomarker for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma Patients.
Dietrich D; Weider S; de Vos L; Vogt TJ; Färber M; Zarbl R; Hunecke A; Glosch AK; Gabrielpillai J; Bootz F; Bauernfeind FG; Kramer FJ; Kristiansen G; Brossart P; Strieth S; Franzen A
Clin Chem; 2023 Sep; 69(9):1050-1061. PubMed ID: 37477541
[TBL] [Abstract][Full Text] [Related]
8. Aberrant methylation inactivates somatostatin and somatostatin receptor type 1 in head and neck squamous cell carcinoma.
Misawa K; Misawa Y; Kondo H; Mochizuki D; Imai A; Fukushima H; Uehara T; Kanazawa T; Mineta H
PLoS One; 2015; 10(3):e0118588. PubMed ID: 25734919
[TBL] [Abstract][Full Text] [Related]
9. NDN and CD1A are novel prognostic methylation markers in patients with head and neck squamous carcinomas.
Virani S; Bellile E; Bradford CR; Carey TE; Chepeha DB; Colacino JA; Helman JI; McHugh JB; Peterson LA; Sartor MA; Taylor JM; Walline HM; Wolf GT; Rozek LS
BMC Cancer; 2015 Oct; 15():825. PubMed ID: 26518708
[TBL] [Abstract][Full Text] [Related]
10. PDCD1 (PD-1) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients.
Goltz D; Gevensleben H; Dietrich J; Schroeck F; de Vos L; Droege F; Kristiansen G; Schroeck A; Landsberg J; Bootz F; Dietrich D
Oncotarget; 2017 Jun; 8(25):41011-41020. PubMed ID: 28487502
[TBL] [Abstract][Full Text] [Related]
11. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
Harbeck N; Nimmrich I; Hartmann A; Ross JS; Cufer T; Grützmann R; Kristiansen G; Paradiso A; Hartmann O; Margossian A; Martens J; Schwope I; Lukas A; Müller V; Milde-Langosch K; Nährig J; Foekens J; Maier S; Schmitt M; Lesche R
J Clin Oncol; 2008 Nov; 26(31):5036-42. PubMed ID: 18711169
[TBL] [Abstract][Full Text] [Related]
12. Correlation of gene methylation in surgical margin imprints with locoregional recurrence in head and neck squamous cell carcinoma.
Hayashi M; Wu G; Roh JL; Chang X; Li X; Ahn J; Goldsmith M; Khan Z; Bishop J; Zhang Z; Zhou XC; Richmon J; Agrawal N; Koch WM
Cancer; 2015 Jun; 121(12):1957-65. PubMed ID: 25773145
[TBL] [Abstract][Full Text] [Related]
13. The Association and Clinical Significance of CDKN2A Promoter Methylation in Head and Neck Squamous Cell Carcinoma: a Meta-Analysis.
Zhou C; Shen Z; Ye D; Li Q; Deng H; Liu H; Li J
Cell Physiol Biochem; 2018; 50(3):868-882. PubMed ID: 30355925
[TBL] [Abstract][Full Text] [Related]
14. Telomeric Repeat-Containing RNAs (TERRA) Decrease in Squamous Cell Carcinoma of the Head and Neck Is Associated with Worsened Clinical Outcome.
Vitelli V; Falvo P; G Nergadze S; Santagostino M; Khoriauli L; Pellanda P; Bertino G; Occhini A; Benazzo M; Morbini P; Paulli M; Porta C; Giulotto E
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29342094
[TBL] [Abstract][Full Text] [Related]
15. Gene promoter methylation signature predicts survival of head and neck squamous cell carcinoma patients.
Kostareli E; Hielscher T; Zucknick M; Baboci L; Wichmann G; Holzinger D; Mücke O; Pawlita M; Del Mistro A; Boscolo-Rizzo P; Da Mosto MC; Tirelli G; Plinkert P; Dietz A; Plass C; Weichenhan D; Hess J
Epigenetics; 2016; 11(1):61-73. PubMed ID: 26786582
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic inactivation of galanin and GALR1/2 is associated with early recurrence in head and neck cancer.
Misawa K; Misawa Y; Kanazawa T; Mochizuki D; Imai A; Endo S; Carey TE; Mineta H
Clin Exp Metastasis; 2016 Feb; 33(2):187-95. PubMed ID: 26572146
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the methylation profile of exfoliated cell samples from patients with head and neck squamous cell carcinoma.
Longo AL; Rettori MM; de Carvalho AC; Kowalski LP; Carvalho AL; Vettore AL
Head Neck; 2014 May; 36(5):631-7. PubMed ID: 23595968
[TBL] [Abstract][Full Text] [Related]
18. Ultra-deep targeted sequencing of advanced oral squamous cell carcinoma identifies a mutation-based prognostic gene signature.
Chen SJ; Liu H; Liao CT; Huang PJ; Huang Y; Hsu A; Tang P; Chang YS; Chen HC; Yen TC
Oncotarget; 2015 Jul; 6(20):18066-80. PubMed ID: 25980437
[TBL] [Abstract][Full Text] [Related]
19. MiR-21 as prognostic biomarker in head and neck squamous cell carcinoma patients undergoing an organ preservation protocol.
Arantes LM; Laus AC; Melendez ME; de Carvalho AC; Sorroche BP; De Marchi PR; Evangelista AF; Scapulatempo-Neto C; de Souza Viana L; Carvalho AL
Oncotarget; 2017 Feb; 8(6):9911-9921. PubMed ID: 28039483
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
